Soft Tissue Leiomyosarcoma With Microsatellite Instability, High Tumor Mutational Burden, and Programmed Death Ligand-1 Expression Showing Pathologic Complete Response to Pembrolizumab: A Case Report

Timothy Kwang Yong Tay, MBBS1; Joe Poh Sheng Yeong, MBBS, MMed(Path), PhD1,2; Eileen Xueqin Chen, PhD3; Xin Xiu Sam, BSc1; Johnathan Xande Lim, BSc1; and Jason Yongsheng Chan, MBBS, PhD4,5

JCO Precis Oncol 6:e2200068. © 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License

Introduction

Locally advanced/metastatic sarcomas generally have a poor prognosis with limited therapeutic options. Pembrolizumab has been shown to be efficacious in solid tumors with deficient mismatch repair (MMRd) or high level of microsatellite instability (MSI-H).1-3 Response to pembrolizumab was also found to be associated with a high tumor mutational burden (TMB) of 10 mutations/megabase (Mb) or more in solid tumors.4 Sarcomas are, however, severely under-represented in the studies that yielded these findings. Programmed death ligand-1 (PD-L1) protein expression has also been included as an US Food and Drug Administration–approved predictive biomarker for programmed cell death protein 1 (PD-1) inhibitor therapy in various carcinomas but not for sarcomas, with the thresholds of PD-L1 expression predicting response to PD-1 inhibitor therapy in sarcomas still being undefined. There are also little data on how MSI-H status correlates with TMB and PD-L1 expression in sarcomas and to what extent each biomarker predicts response to PD-1 inhibitor therapy. In this case report, we describe a metastatic leiomyosarcoma with MSI-H status, high TMB (>10 mutations/Mb), and significant PD-L1 expression, showing pathologic complete response to pembrolizumab, a PD-1 inhibitor.

Case Presentation

The patient is a 54-year-old Malay male who first presented with an enlarging abdominal wall mass. Computed tomography imaging revealed a heterogeneous soft tissue mass centered in the left rectus muscle measuring 7.0 × 5.2 × 8.8 cm with no distant metastases. Open excision of the tumor was performed, with clear resection margins of 2-3 mm achieved.

This study was approved by a centralized institutional ethics review board. Informed consent was obtained from the patient for the tests performed.

Histologic examination of the tumor showed a neoplasm composed of fascicles of malignant spindle cells, with eosinophilic cytoplasm (Fig 1) showing multifocal positivity for desmin and caldesmon on immunohistochemistry (IHC), in keeping with a leiomyosarcoma, FNCLCC grade 3. Fluorescence in situ hybridization for MDM2 amplification was negative, excluding a dedifferentiated liposarcoma. A diagnosis of stage IIIB leiomyosarcoma of the rectus was made. No adjuvant therapy was administered.

Four months later, computed tomography imaging revealed a new 4.5 cm internal mammary nodal mass, local recurrence of tumor in the remnant left rectus abdominis muscle measuring 4.4 cm, and a large 8.8 cm intra-abdominal mass arising from the omentum, consistent with locally recurrent and metastatic disease. The disease continued to progress despite three cycles of 4-weekly pegylated liposomal doxorubicin, followed by two cycles of 3-weekly pegylated liposomal doxorubicin, followed by two cycles of 3-weekly gemcitabine and docetaxel.

Tumor tissue from the excision specimen was then sent for molecular profiling using the FoundationOne CDx assay. A MSH6 R922* truncating mutation was found, along with somatic mutations in TP53, BCL2, and MLL2 and other truncating mutations in RB1 and MSH3. TMB was 11.35 mutations/Mb, and microsatellite instability (MSI) status was reported as MSI-H.

MSI-PCR performed in our institution showed a shift in three (NR27, BAT25, and BAT26) of the five MSI marker profiles (Fig 2), confirming the MSI-H status. IHC for DNA mismatch repair proteins (MMR IHC) also showed absent expression for MSH6 protein, whereas MLH1, MSH2, and PMS2 expression was retained (Fig 3). The patient, however, does not have any family history or history of cancer to suggest the possibility of Lynch syndrome.

On review of the excised tumor, it was observed that the tumor has a mild to moderate infiltrate of lymphocytes and plasma cells, especially at the
FIG 1. Histology of the excised abdominal wall tumor shows fascicles of atypical spindle cells with (A) eosinophilic cytoplasm and (B) areas of necrosis. Immunohistochemistry shows the tumor cells staining positive for (C) desmin and (D) caldesmon. The features are in keeping with a leiomyosarcoma.

FIG 2. MSI-polymerase chain reaction shows a shift in three of the five MSI marker profiles (NR27, BAT25, and BAT 26) when comparing tumor with normal DNA, in keeping with MSI high status: (A) germline and (B) tumor. MSI, microsatellite instability.
tumor-stroma interface, in keeping with TILs. There was, however, no aggregation of the lymphoid cells to suggest the presence of tertiary lymphoid structures. IHC for CD3 and CD20 showed that a majority of TILs are CD3+ T cells with a smaller number of CD20+ B-cells (Figs 4A-4C). PD-L1 (22C3 clone) IHC showed staining of both the tumor cells and the immune cells with an estimated Tumor Proportion Score of 40% and a Combined Positive Score of 50 (Fig 4D).

Direct visualization of the tumor-infiltrating immune cells with multiplex IHC/immunofluorescence showed that the immune cells include CD8+ T cells (CD8-positive, 15.6%) and macrophages (CD68-positive, 18.5%). Regulatory T cells (FOXP3-positive, 3.3%) were relatively infrequent.
PD-L1–positive cells (19.7%) were diffusely scattered throughout the tumor (Fig 5).

The patient then received palliative radiation therapy to the internal mammary nodal mass, before commencing on pembrolizumab 100 mg administered every 3 weeks following the knowledge that the tumor was MSI-H. This dosage of pembrolizumab was chosen because of the cost of the drug, and prevailing local reimbursement policies made it more affordable for the patient at this dosage. After three cycles, imaging showed a decrease in size of both the internal mammary adenopathy (6.3 cm to 4.4 cm) and omental mass (12.1 cm to 11.2 cm), the latter now contiguous with the rectus tumor and containing specks of gas suggestive of fistulation into adjacent bowel (Figs 6A and 6B). The patient also developed progressive subcutaneous abdominal wall abscess and small bowel intestinal obstruction. A decision was then made for the patient to undergo wide excision of the omental/rectus tumor with en bloc small bowel resection and subtotal colectomy.

Histologic examination of the omental/rectus tumor, however, showed extensive necrosis with no residual viable tumor, in keeping with pathologic complete response (Figs 6C and 6D).

Post-surgery, the patient underwent 10 cycles of pembrolizumab. A surveillance scan at 3 months and 6 months postsurgery did not reveal any local or distant disease recurrence, whereas the internal mammary nodal mass remained stable in size.

Discussion

The incidence of MSI-H and MMRd in sarcomas reported in the published literature varies widely from < 1% to > 25%. The contradictory findings from the different studies are likely due to many factors including difference in sample sizes, heterogeneity of the sarcoma subtypes studied, and difference in methodology used including the type of microsatellite marker. The studies that report a higher incidence of MSI-H/MMRd status tend to be older studies with smaller sample sizes, whereas more recent contemporary studies or studies with larger sample sizes tend to report an incidence of around 1%-2%, which is likely more reflective of the true incidence. Most MSI-H/MMRd sarcomas contain mutations in MSH2 or MLH1, whereas MSH6 mutations (which was seen in our case) and PMS2 mutations form the minority, with an incidence of 11.6% and 2.3% of cases, respectively, in one study.

Data on how MSI-H/MMRd status correlates with response to immune checkpoint inhibitor (ICI) therapy in sarcomas remain scant. In a recent study by Doyle et al, three of seven MMRd sarcomas were treated with pembrolizumab. One patient had stable disease, whereas another had disease progression after 4 months of treatment. The third patient died from rapidly progressive disease postsurgical resection after receiving pembrolizumab for only 1.5 months. In another case report by Wang et al, a patient with a MSI-H uterine leiomyosarcoma showed partial response to pembrolizumab after three cycles but ultimately had disease progression after seven cycles. Our case therefore adds to the existing published data of response of MSI-H/MMRd sarcoma to ICI, albeit showing an extremely favorable response. Other case reports of sarcomas showing complete or partial response to ICI do not report the MSI-H/MMRd status.
Data correlating the presence of MSI-H/MMRd status with TMB are also lacking in sarcomas. In the study by Doyle et al,14 six of the seven MSI-H/MMRd sarcomas had a TMB of > 10 mutations/Mb (ranging from 12.2 to 25.9) with the remaining tumor having a TMB of 9.1. The TMB in MMRd sarcomas was observed to be significantly higher than that in MMR-proficient sarcomas (median mutational burden of 16 ± 4.6, P < .001). This suggests that MSI-H/MMRd sarcomas are likely to have a TMB that exceeds 10. The correlation of MSI-H/MMRd status with PD-L1 expression in sarcomas is more variable. Of the seven MSI-H/MMRd sarcomas in the same study, three had 0%-2% of intratumoral immune cells showing PD-L1 expression, whereas the remaining four had PD-L1 expression in 10%-50% of the intratumoral immune cells. The three tumors with low PD-L1 expression were the three tumors that were treated with pembrolizumab in the study, which may explain their nonresponse to the drug despite the MSI-H/MMRd and high TMB status of the tumors (two of the three cases had TMB of 13.7 and 16.0, whereas the remaining had TMB of 9.1). However, response to ICIs has been reported to occur even in the absence of PD-L1 expression.22-25 In addition, an angiosarcoma with a low TMB showing complete response to an ICI has also been reported, suggesting that TMB is also not entirely reliable in predicting response to immunotherapy.26 In a study by Lam et al,15 the authors found that the level of PD-L1 expression also correlated with the degree of T-lymphocyte infiltration in the tumor, an observation echoed by other studies.27-30 In the SARC028 phase II clinical trial, patients with advanced sarcomas that responded to pembrolizumab had higher densities of activated T cells (CD8+CD3+PD-1+) and increased percentage of tumor-associated macrophages expressing PD-L1 compared with nonresponders.31 Our case of leiomyosarcoma has a relatively high expression of PD-L1 in the tumor cells in addition to MSI-H/MMRd status and elevated TMB of > 10 mutations/Mb. Although MSI-H/MMRd status is not a guarantee of response to ICI as seen in the study by Doyle et al, it is uncertain if the marked response to ICI in our case is due to the high PD-L1 expression or high TMB. Each biomarker on its own has been found to be not always predictive of ICI response as discussed above, and it is likely that the constellation of factors of MSI-H/MMRd status, high TMB, high expression of PD-L1 in the tumor cells, and even the presence of TILs has poised the immune cells to greatly destroy the tumor in this case when immune checkpoint blockade was applied. This suggests that perhaps a multifactorial assessment of MSI-H/MMRd status, TMB, PD-L1 expression, and TILs may be more useful in predicting ICI response in sarcoma than relying on one parameter alone. More study will be required to further refine the use of biomarkers in predicting ICI response in sarcomas.

FIG 6. Computed tomography scans (A) before and (B) after three cycles of pembrolizumab treatment, showing decrease in size of the internal mammary adenopathy and marginal decrease in size of the omental metastasis, which is now contiguous with the recurrent rectus tumor. Excision of the omental/rectus tumor, however, showed (C) an extensive necrotic tumor (indicated with arrow), which was confirmed microscopically to harbor (D) no residual viable tumor, in keeping with pathologic complete response.
AFFILIATIONS
1 Department of Anatomical Pathology, Singapore General Hospital, Singapore
2 Institute of Molecular and Cell Biology, Singapore
3 Department of Molecular Pathology, Singapore General Hospital, Singapore
4 Oncology Academic Clinical Program, Duke-NUS Medical School, Singapore
5 Division of Medical Oncology, National Cancer Center Singapore, Singapore

CORRESPONDING AUTHOR
Jason Yongsheng Chan, MBBS, PhD, Oncology Academic Clinical Program, Duke-NUS Medical School, Singapore, Division of Medical Oncology, National Cancer Center Singapore, 11 Hospital Crescent, Singapore 169610; e-mail: jason.chan.y.s@nccs.com.sg.

SUPPORT
Supported by the Singapore Ministry of Health’s National Medical Research Council under its Transition Award (TA21jun-0005) and RTF Seed Fund (SEEDFD21jun-0002), as well as SingHealth Duke-NUS Academic Medical Centre and Oncology ACP Nurturing Clinician Scientist Scheme (08-FY2017/P1/14-A28), Sarcoma Research Fund (08-FY2020/EX75-A151), and SHF-Foundation Research Grant (SHF/FG653P/2017).

DATA SHARING STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES
1. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509-2520, 2015
2. Le DT, Durham JN, Smith KN, et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409-413, 2017
3. Marabelle A, Le DT, Ascierto PA, et al: Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 38:1-10, 2020
4. Marabelle A, Fakih M, Lopez J, et al: Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21:1353-1365, 2020
5. Amant F, Dorfling CM, Dreyer L, et al: Microsatellite instability in uterine sarcomas. Int J Gynecol Cancer 11:218-223, 2001
6. Saito T, Oda Y, Kawaguchi K, et al: Possible association between tumor-suppressor gene mutations and hMSH2/hMLH1 inactivation in alveolar soft part sarcoma. Hum Pathol 34:841-849, 2003
7. Ericson K, Engellau J, Persson A, et al: Immunohistochemical loss of the DNA mismatch repair proteins MSH2 and MSH6 in malignant fibrous histiocytomas. Sarcoma 8:123-127, 2004
8. Garcia JJ, Kramer MJ, O’Donnell RJ, et al: Mismatch repair protein expression and microsatellite instability: A comparison of clear cell sarcoma of soft parts and metastatic melanoma. Mod Pathol 19:950-957, 2006
9. Monument MJ, Lessnick SL, Schiffman JD, et al: Microsatellite instability in sarcoma: Fact or fiction? ISRN Oncol 2012:473146, 2012
10. Hoang LN, Ali RH, Lau S, et al: Immunohistochemical survey of mismatch repair protein expression in uterine sarcomas and carcinosarcomas. Int J Gynecol Pathol 33:483-491, 2014
11. Campanella NC, Penna V, Ribeiro G, et al: Absence of microsatellite instability in soft tissue sarcomas. Pathobiology 82:36-42, 2015
12. Bonniville R, Krook MA, Kauto EA, et al: Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol 10.1200/PO.17.00073 [epub ahead of print on October 3, 2017]
13. Kim ST, Klemperer SJ, Park SH, et al: Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: Implications for immunotherapy. Onco-target 8:77415-77423, 2017
14. Doyle LA, Nowak JA, Nathenson MJ, et al: Characteristics of mismatch repair deficiency in sarcomas. Mod Pathol 32:977-987, 2019
15. Lam SW, Kostine M, de Miranda NFCC, et al: Mismatch repair deficiency is rare in bone and soft tissue tumors. Histopathology 79:509-520, 2021
16. de Carvalho NA, Nitsurna BN, Kozak VN, et al: Clinical and molecular assessment of patients with Lynch syndrome and sarcomas underpinning the association with MSH2 germline pathogenic variants. Cancers (Basel) 12:1848, 2020
17. Wang YJ, Williams HR, Brzezinska BN, et al: Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature. Gynecol Oncol Rep 35:100701, 2021
18. Momen S, Fasshi H, Davies HR, et al: Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: Whole-genome sequencing aids treatment decision in end-stage disease. Cold Spring Harb Mol Case Stud 5:a004408, 2019
19. Conley AP, Trinh VA, Zobniw CM, et al: Positive tumor response to combined checkpoint inhibitors in a patient with refractory alveolar soft part sarcoma: A case report. J Glob Oncol 4:1-6, 2018

AUTHOR CONTRIBUTIONS
Conception and design: Jason Yongsheng Chan
Financial support: Jason Yongsheng Chan
Administrative support: Jason Yongsheng Chan
Provision of study materials or patients: Timothy Kwang Yong Tay, Xin Xiu Sam, J ohnathan Xiande Lim, Jason Yongsheng Chan
Collection and assembly of data: All authors
Data analysis and interpretation: Timothy Kwang Yong Tay, Joe Poh Sheng Yeong, Eileen Xueqin Chen, Jason Yongsheng Chan
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/fwc or ascopubs.org/po/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
No potential conflicts of interest were reported.
20. Marcrom S, De Los Santos JF, Conry RM, et al: Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy. Clin Sarcoma Res 7:14, 2017
21. Guram K, Nunez M, Einck J, et al: Radiation therapy combined with checkpoint blockade immunotherapy for metastatic undifferentiated pleomorphic sarcoma of the maxillary sinus with a complete response. Front Oncol 8:435, 2018
22. D’Angelo SP, Shoushtari AN, Agaram NP, et al: Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol 46:357-365, 2015
23. Zhou M, Bui N, Lohman M, et al: Long-term remission with ipilimumab/nivolumab in two patients with different soft tissue sarcoma subtypes and no PD-L1 expression. Case Rep Oncol 14:459-465, 2021
24. Liu J, Fan Z, Bai C, et al: Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma. Ann Transl Med 9:339, 2021
25. Italiano A, Bellera C, D’Angelo S: PD1/PD-L1 targeting in advanced soft-tissue sarcomas: A pooled analysis of phase II trials. J Hematol Oncol 13:55, 2020
26. Florou V, Rosenberg AE, Weder E, et al: Angiosarcoma patients treated with immune checkpoint inhibitors: A case series of seven patients from a single institution. J Immunother Cancer 7:213, 2019
27. Ishihara S, Yamada Y, Iwasaki T, et al: PD-L1 and IDO-1 expression in undifferentiated pleomorphic sarcoma: The associations with tumor infiltrating lymphocytes, dMMR and HLA class I. Oncol Rep 45:379-389, 2021
28. Orth MF, Buecklein VL, Kampmann E, et al: A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas. Cancer Immunol Immunother 69:1353-1362, 2020
29. Boxberg M, Steiger K, Lenze U, et al: PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue—Prognostic implications and rationale for immunotherapy. Oncoimmunology 7:e1389366, 2017
30. Que Y, Xiao W, Guan Y, et al: PD-L1 expression is associated with FOXP3+ regulatory T-cell infiltration of soft tissue sarcoma and poor patient prognosis. J Cancer 8:2018-2025, 2017
31. Keung EZ, Burgess M, Salazar R, et al: Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab. Clin Cancer Res 26:1258-1266, 2020